In recent trading session, Clover Health Investments Corp (NASDAQ:CLOV) saw 1.03 million shares changing hands at last check today with its beta currently measuring 1.99. Company’s recent per share price level of $3.65 trading at $0.19 or 5.46% at last check today assigns it a market valuation of $1.86B. That most recent trading price of CLOV’s stock is at a discount of -33.42% from its 52-week high price of $4.87 and is indicating a premium of 83.29% from its 52-week low price of $0.61. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.0 million shares which gives us an average trading volume of 6.17 million if we extend that period to 3-months.

For Clover Health Investments Corp (CLOV), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.

Clover Health Investments Corp (NASDAQ:CLOV) trade information

Upright in the green today for gaining 5.46%, in the last five days CLOV remained trading in the green while hitting it’s week-highest on Thursday, 03/13/25 when the stock touched $3.65 price level, adding 1.35% to its value on the day. Clover Health Investments Corp’s shares saw a change of 15.84% in year-to-date performance and have moved 0.25% in past 5-day. Clover Health Investments Corp (NASDAQ:CLOV) showed a performance of -18.37% in past 30-days. Number of shares sold short was 11.9 million shares which calculate 2.24 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 39.17% to its recent value today. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -64.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -64.38% for stock’s current value.

Clover Health Investments Corp (CLOV) estimates and forecasts

This year revenue growth is estimated to rise 36.00% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 466.93M for the same. And 4 analysts are in estimates of company making revenue of 474.88M in the next quarter. Company posted 346.92M and 356.26M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -237.67% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -80.25% while estimates for its earnings growth in next 5 years are of 40.98%.

Clover Health Investments Corp (NASDAQ:CLOV)’s Major holders

Insiders are in possession of 5.09% of company’s total shares while institution are holding 22.38 percent of that, with stock having share float percentage of 23.58%. Investors also watch the number of corporate investors in a company very closely, which is 22.38% institutions for Clover Health Investments Corp that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at CLOV for having 17.35 million shares of worth $21.33 million. And as of 2024-06-30, it was holding 3.5662 of the company’s outstanding shares.

The second largest institutional holder is RENAISSANCE TECHNOLOGIES LLC, which was holding about 11.27 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.3123 of outstanding shares, having a total worth of $13.86 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 10.96 shares of worth $39.89 million or 2.62% of the total outstanding shares. The later fund manager was in possession of 6.22 shares on Dec 31, 2024, making its stake of worth around $22.62 million in the company or a holder of 1.49% of company’s stock.